Laura Graham, MD, discusses phase 1 safety and PSA response data for JNJ-87189401 plus pasritamig in metastatic castration-resistant prostate cancer.

Johnson & Johnson has reported promising Phase 1 results for pasritamig and JNJ-9401, a new immunotherapy combination for advanced prostate cancer, showing a 73% PSA response rate.

Reported Sunday, Nov 8 - 3:26pm EST (TheFly subscription required to read more.)

Johnson & Johnson reported a 73% PSA response rate in Phase 1 results for its investigational pasritamig-based immunotherapy combination in advanced prostate cancer. The dual-antigen-targeted regimen showed significant efficacy with no Grade 3 or higher treatment-related adverse events in the small patient cohort.

Jim.henderson / Wikimedia Commons / CC BY-SA 4.0 Johnson & Johnson reported Sunday that a blood marker used to track prostate cancer fell by at least half in 11 of 15 patients receiving a selected regimen of an experimental two-drug treatment. The early results concern pasritamig combined with JNJ-9401 in people with metastatic castration-resistant prostate cancer, an advanced form that has spread and continues to progress despite treatment targeting the hormone pathway that helps it grow.

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse ev...

The treatment, called Pasritamig, teaches the immune system's T cells to target and attack cancer cells in the prostate.

GI Innovation and Johnson & Johnson are testing a combination immunotherapy in metastatic castration-resistant prostate cancer. Here's what the trial means.

Pasritamig (JNJ-78278343) is a KLK2×CD3 bispecific antibody for mCRPC, showing early efficacy with manageable CRS and outpatient-friendly dosing.

Johnson & Johnson (NYSE:JNJ) is one of the 10 best stocks to invest in during a recession. On February 26, 2026, Johnson & Johnson (NYSE:JNJ) provided an update, reporting promising Phase 1b data for pasritamig, a pioneering bispecific T-cell engager, combined with docetaxel for metastatic castration-resistant prostate cancer. The study was unveiled at the 2026 […]

Ginkgo Bioworks sells biosecurity unit to investor consortium for minority equity stake. J&J's pasritamig shows promise in prostate cancer, reducing PSA levels in 64.7% of patients.

Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer (mCRPC).

GI Innovation and Johnson & Johnson are testing a combination immunotherapy in metastatic castration-resistant prostate cancer. Here's what the trial means.

Reported Thursday, Feb 26 - 2:53pm EST (TheFly subscription required to read more.)

Recent findings from Johnson & Johnson highlight pasritamig's effectiveness when used with docetaxel for advanced prostate cancer, paving the way for Phase 3 trials.

Johnson & Johnson has announced encouraging results for their new bispecific antibody, pasritamig, in prostate cancer treatment, demonstrating early anti-tumor activity.

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3. Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate cancer. RARITAN, N.J., Feb. 26, 2026/ PRNewswire/-- Johnson& Johnson today announced preliminary results from a Phase 1 b...

Zymeworks (NASDAQ: ZYME) announced a strategic initiative to optimize value from licensed products by building a diversified portfolio of revenue-generating healthcare assets while retaining in-house R&D capabilities.Key elements: potential near-term Ziihera GEA regulatory milestones of $440.0M, pasritamig milestones of $434.0M plus royalties, a new $125.0M share repurchase authorization, and reported cash, cash equivalents and investments of $299.4M as of Sept 30, 2025.

David R. Wise, MD, PhD, discusses the safety profile of pasritamig plus docetaxel in patients with mCRPC.

David R. Wise, MD, PhD, discusses the efficacy of pasritamig plus docetaxel in patients with mCRPC.

David R. Wise, MD, PhD, unpacks the design of a phase 1b trial of pasritamig plus docetaxel in mCRPC.